Critically, the lack of MYCN amplification without either 1p loss or 17q gain further limits the role of MYCN in distinguishing those patients who are likely to survive from those that are destined to fail treatment [33]. Moreover, long-term survival of advanced neuroblastoma patients with MYCN amplification has also been reported [34]. The gene discussed is MYCN; the disease is neuroblastoma.